HIV - Human Immunodeficiency Virus
Conditions
Keywords
coronary calcium, coronary calcification, cardiovascular risk, major adverse cardiovascular events
Brief summary
The risk of atherosclerotic cardiovascular disease is increased in people with HIV infection, including young patients and those with few traditional cardiovascular risk factors. The increased risk of cardiovascular disease among people living with HIV is due to accelerated atherosclerosis, caused by chronic inflammation and immune dysregulation. The measurement of coronary calcium using plain computed tomography is a subclinical indicator of coronary atherosclerosis and is associated with the risk of cardiovascular events and mortality in the general population.
Detailed description
Therefore, the primary objective is to assess the coronary calcium score in patients with chronic retroviral infection using plain coronary CT scan. In addition to correlating coronary calcium scores with patients' clinical and biochemical variables, and determining whether the coronary calcium score influences patients' subsequent treatment.
Interventions
DIAGNOSTIC_TESTSimple coronary CT scan
All patients will undergo a standard coronary CT scan to measure coronary calcium
Sponsors
Instituto Mexicano del Seguro Social
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who have been diagnosed with HIV infection for more than 6 months * Undetectable viral load
Exclusion criteria
* Patients who have previously taken statins * Patients with chronic ischemic heart disease that has required stenting or revascularization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Coronary calcium | Baseline | The result is expressed in points using the Agatston scale and indicates the level of risk: * 0 points: No calcium. Very low risk. No significant coronary artery disease apparent at the time of the study. * 1 to 99 points: Mild calcified plaque. There is a mild risk of heart disease. * 100 to 300 points: Moderate plaque. Moderate risk of heart disease. * More than 300 points: Extensive plaque. High risk of heart disease and heart attack. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular risk | Baseline | For every patient who meets the inclusion criteria, cardiovascular risk will be assessed using the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations estimate 10-year and 30-year risk for total cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD) and heart failure. It is classified as follows: * Low risk: Less than 5% * Borderline risk: 5% to 7.4% * Intermediate risk: 7.5% to 19.9% * High risk: 20% or more |
| Major adverse cardiovascular events | Through study completion, an average of 4 years. | The occurrence of major adverse cardiovascular events will be assessed: acute myocardial infarction, stroke, and cardiovascular death |
Countries
Mexico
Contacts
CONTACTHilda E. Macias-Cervantes, PhD
CONTACTIrma N. Rocha-Salazar, MD
Outcome results
None listed